![]() |
||||||
|
![]() | Fusion Gene Summary |
![]() | Fusion Gene ORF analysis |
![]() | Fusion Genomic Features |
![]() | Fusion Protein Features |
![]() | Fusion Gene Sequence |
![]() | Fusion Gene PPI analysis |
![]() | Related Drugs |
![]() | Related Diseases |
Fusion gene:ZNF416-ACTN4 (FusionGDB2 ID:HG55659TG81) |
Fusion Gene Summary for ZNF416-ACTN4 |
![]() |
Fusion gene information | Fusion gene name: ZNF416-ACTN4 | Fusion gene ID: hg55659tg81 | Hgene | Tgene | Gene symbol | ZNF416 | ACTN4 | Gene ID | 55659 | 81 |
Gene name | zinc finger protein 416 | actinin alpha 4 | |
Synonyms | - | ACTININ-4|FSGS|FSGS1 | |
Cytomap | ('ZNF416')('ACTN4') 19q13.43 | 19q13.2 | |
Type of gene | protein-coding | protein-coding | |
Description | zinc finger protein 416 | alpha-actinin-4focal segmental glomerulosclerosis 1non-muscle alpha-actinin 4 | |
Modification date | 20200313 | 20200327 | |
UniProtAcc | . | O43707 | |
Ensembl transtripts involved in fusion gene | ENST00000196489, | ||
Fusion gene scores | * DoF score | 3 X 3 X 3=27 | 27 X 38 X 12=12312 |
# samples | 4 | 48 | |
** MAII score | log2(4/27*10)=0.567040592723894 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(48/12312*10)=-4.68088692071969 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: ZNF416 [Title/Abstract] AND ACTN4 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | ZNF416(58089425)-ACTN4(39191240), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | ZNF416-ACTN4 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ZNF416-ACTN4 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ZNF416-ACTN4 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ZNF416-ACTN4 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | ACTN4 | GO:0033209 | tumor necrosis factor-mediated signaling pathway | 25411248 |
Tgene | ACTN4 | GO:0035357 | peroxisome proliferator activated receptor signaling pathway | 22351778 |
Tgene | ACTN4 | GO:0048384 | retinoic acid receptor signaling pathway | 22351778 |
Tgene | ACTN4 | GO:0051272 | positive regulation of cellular component movement | 9508771 |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | SARC | TCGA-3B-A9HX-01A | ZNF416 | chr19 | 58089425 | - | ACTN4 | chr19 | 39191240 | + |
Top |
Fusion Gene ORF analysis for ZNF416-ACTN4 |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
5CDS-intron | ENST00000196489 | ENST00000390009 | ZNF416 | chr19 | 58089425 | - | ACTN4 | chr19 | 39191240 | + |
5CDS-intron | ENST00000196489 | ENST00000497637 | ZNF416 | chr19 | 58089425 | - | ACTN4 | chr19 | 39191240 | + |
In-frame | ENST00000196489 | ENST00000252699 | ZNF416 | chr19 | 58089425 | - | ACTN4 | chr19 | 39191240 | + |
In-frame | ENST00000196489 | ENST00000424234 | ZNF416 | chr19 | 58089425 | - | ACTN4 | chr19 | 39191240 | + |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000196489 | ZNF416 | chr19 | 58089425 | - | ENST00000252699 | ACTN4 | chr19 | 39191240 | + | 5023 | 298 | 145 | 2871 | 908 |
ENST00000196489 | ZNF416 | chr19 | 58089425 | - | ENST00000424234 | ACTN4 | chr19 | 39191240 | + | 1702 | 298 | 145 | 1701 | 519 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000196489 | ENST00000252699 | ZNF416 | chr19 | 58089425 | - | ACTN4 | chr19 | 39191240 | + | 0.008230717 | 0.9917693 |
ENST00000196489 | ENST00000424234 | ZNF416 | chr19 | 58089425 | - | ACTN4 | chr19 | 39191240 | + | 0.006395498 | 0.9936045 |
Top |
Fusion Genomic Features for ZNF416-ACTN4 |
![]() |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
ZNF416 | chr19 | 58089424 | - | ACTN4 | chr19 | 39191239 | + | 1.81E-06 | 0.9999982 |
ZNF416 | chr19 | 58089424 | - | ACTN4 | chr19 | 39191239 | + | 1.81E-06 | 0.9999982 |
![]() |
![]() |
![]() |
![]() |
Top |
Fusion Protein Features for ZNF416-ACTN4 |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:58089425/chr19:39191240) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
Hgene | Tgene |
. | ACTN4 |
FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. | FUNCTION: F-actin cross-linking protein which is thought to anchor actin to a variety of intracellular structures. This is a bundling protein (Probable). Probably involved in vesicular trafficking via its association with the CART complex. The CART complex is necessary for efficient transferrin receptor recycling but not for EGFR degradation (PubMed:15772161). Involved in tight junction assembly in epithelial cells probably through interaction with MICALL2. Links MICALL2 to the actin cytoskeleton and recruits it to the tight junctions (By similarity). May also function as a transcriptional coactivator, stimulating transcription mediated by the nuclear hormone receptors PPARG and RARA (PubMed:22351778). {ECO:0000250|UniProtKB:P57780, ECO:0000269|PubMed:15772161, ECO:0000269|PubMed:22351778, ECO:0000305|PubMed:9508771}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 778_789 | 54 | 912.0 | Calcium binding | 1 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 819_830 | 54 | 912.0 | Calcium binding | 2 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 778_789 | 0 | 693.0 | Calcium binding | 1 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 819_830 | 0 | 693.0 | Calcium binding | 2 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 19_26 | 0 | 693.0 | Compositional bias | Poly-Gly | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 163_269 | 54 | 912.0 | Domain | Calponin-homology (CH) 2 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 765_800 | 54 | 912.0 | Domain | EF-hand 1 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 806_841 | 54 | 912.0 | Domain | EF-hand 2 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 163_269 | 0 | 693.0 | Domain | Calponin-homology (CH) 2 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 50_154 | 0 | 693.0 | Domain | Calponin-homology (CH) 1 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 765_800 | 0 | 693.0 | Domain | EF-hand 1 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 806_841 | 0 | 693.0 | Domain | EF-hand 2 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 84_88 | 54 | 912.0 | Motif | LXXLL motif | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 84_88 | 0 | 693.0 | Motif | LXXLL motif | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 177_192 | 54 | 912.0 | Region | Polyphosphoinositide (PIP2)-binding | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 177_192 | 0 | 693.0 | Region | Polyphosphoinositide (PIP2)-binding | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 1_269 | 0 | 693.0 | Region | Note=Actin-binding | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 293_403 | 54 | 912.0 | Repeat | Spectrin 1 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 413_518 | 54 | 912.0 | Repeat | Spectrin 2 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 528_639 | 54 | 912.0 | Repeat | Spectrin 3 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 649_752 | 54 | 912.0 | Repeat | Spectrin 4 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 293_403 | 0 | 693.0 | Repeat | Spectrin 1 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 413_518 | 0 | 693.0 | Repeat | Spectrin 2 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 528_639 | 0 | 693.0 | Repeat | Spectrin 3 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 649_752 | 0 | 693.0 | Repeat | Spectrin 4 |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 28_111 | 25 | 595.0 | Domain | KRAB |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 242_264 | 25 | 595.0 | Zinc finger | C2H2-type 1%3B degenerate |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 270_292 | 25 | 595.0 | Zinc finger | C2H2-type 2 |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 298_320 | 25 | 595.0 | Zinc finger | C2H2-type 3 |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 326_348 | 25 | 595.0 | Zinc finger | C2H2-type 4 |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 354_376 | 25 | 595.0 | Zinc finger | C2H2-type 5 |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 382_404 | 25 | 595.0 | Zinc finger | C2H2-type 6 |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 410_432 | 25 | 595.0 | Zinc finger | C2H2-type 7 |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 438_460 | 25 | 595.0 | Zinc finger | C2H2-type 8 |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 466_488 | 25 | 595.0 | Zinc finger | C2H2-type 9 |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 494_516 | 25 | 595.0 | Zinc finger | C2H2-type 10 |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 522_544 | 25 | 595.0 | Zinc finger | C2H2-type 11 |
Hgene | ZNF416 | chr19:58089425 | chr19:39191240 | ENST00000196489 | - | 2 | 4 | 550_572 | 25 | 595.0 | Zinc finger | C2H2-type 12 |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 19_26 | 54 | 912.0 | Compositional bias | Poly-Gly | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 50_154 | 54 | 912.0 | Domain | Calponin-homology (CH) 1 | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 1_269 | 54 | 912.0 | Region | Note=Actin-binding |
Top |
Fusion Gene Sequence for ZNF416-ACTN4 |
![]() |
>102026_102026_1_ZNF416-ACTN4_ZNF416_chr19_58089425_ENST00000196489_ACTN4_chr19_39191240_ENST00000252699_length(transcript)=5023nt_BP=298nt TTGCATACGGTAAGGCGGGACTTCCGGCACCGCTCCGAGATGGTAATTTTGGTGGTTCTCTACCTCGGCCCACGCCGCCTGAGTTAGAAA CGCTGCCTCCGGCACAGAGCGGGGGTCGCCCCGCTGCGCATCAGCCGGTGGGTCGCTGGCGCTGGTGGCAGCCGTGCCTGGGTTCCCGCC CCGGGTCGCCCGCCGCTCCCGGCCCCGCTCCGCTCACAATCCGATGGCGGCGGCCGTGCTTAGGGATTCGACTTCGGTTCCCGTGACTGC AGAAGCTAAACTTATGGGCTTTACACAGACCTTCACGGCATGGTGCAACTCCCACCTGCGGAAGGCAGGCACACAGATCGAGAACATTGA TGAGGACTTCCGAGACGGGCTCAAGCTCATGCTGCTCCTGGAGGTCATATCAGGGGAGCGGTTACCTAAGCCGGAGCGGGGGAAGATGAG AGTGCACAAAATCAACAATGTGAACAAAGCGCTGGACTTTATTGCCAGCAAAGGCGTCAAGCTGGTCTCCATCGGGGCAGAAGAGATTGT GGACGGCAACGCAAAGATGACCCTGGGAATGATCTGGACCATCATCCTTAGGTTCGCCATCCAGGACATCTCCGTGGAAGAGACCTCGGC CAAGGAAGGGCTCCTTCTCTGGTGCCAGAGAAAGACAGCCCCGTATAAGAACGTCAATGTGCAGAACTTCCACATCAGCTGGAAGGATGG TCTTGCCTTCAATGCCCTGATCCACCGGCACAGACCAGAGCTGATTGAGTATGACAAGCTGAGGAAGGACGACCCTGTCACCAACCTGAA CAATGCCTTCGAAGTGGCTGAGAAATACCTCGACATCCCCAAGATGCTGGATGCAGAGGACATCGTGAACACGGCCCGGCCCGACGAGAA GGCCATAATGACCTATGTGTCCAGCTTCTACCATGCCTTTTCAGGAGCGCAGAAGGCTGAAACTGCCGCCAACCGGATCTGTAAGGTGCT GGCTGTCAACCAAGAGAACGAGCACCTGATGGAGGACTACGAGAAGCTGGCCAGCGACCTCCTGGAGTGGATCCGGCGCACCATCCCCTG GCTGGAGGACCGTGTGCCCCAAAAGACTATCCAGGAGATGCAGCAGAAGCTGGAGGACTTCCGCGACTACCGGCGTGTGCACAAGCCGCC CAAGGTGCAGGAGAAGTGCCAGCTGGAGATCAACTTCAACACGCTGCAGACCAAGCTGCGCCTCAGCAACCGGCCCGCCTTCATGCCCTC CGAGGGCAAGATGGTCTCGGACATCAACAATGGCTGGCAGCACTTGGAGCAGGCTGAGAAGGGCTACGAGGAGTGGCTGCTGAATGAGAT CCGCAGGCTGGAGCGGCTCGACCACCTGGCAGAGAAGTTCCGGCAGAAGGCCTCCATCCACGAGGCCTGGACTGACGGGAAGGAAGCCAT GCTGAAGCACCGGGACTACGAGACGGCCACACTATCGGACATCAAAGCCCTCATTCGCAAGCACGAGGCCTTCGAGAGCGACCTGGCTGC GCACCAGGACCGCGTGGAGCAGATCGCCGCCATTGCCCAGGAGCTCAACGAGCTGGATTACTACGACTCCCACAATGTCAACACCCGGTG CCAGAAGATCTGTGACCAGTGGGACGCCCTCGGCTCTCTGACACATAGTCGCAGGGAAGCCCTGGAGAAAACAGAGAAGCAGCTGGAGGC CATCGACCAGCTGCACCTGGAATACGCCAAGCGCGCGGCCCCCTTCAACAACTGGATGGAGAGCGCCATGGAGGACCTCCAGGACATGTT CATCGTCCATACCATCGAGGAGATTGAGGGCCTGATCTCAGCCCATGACCAGTTCAAGTCCACCCTGCCGGACGCCGATAGGGAGCGCGA GGCCATCCTGGCCATCCACAAGGAGGCCCAGAGGATCGCTGAGAGCAACCACATCAAGCTGTCGGGCAGCAACCCCTACACCACCGTCAC CCCGCAAATCATCAACTCCAAGTGGGAGAAGGTGCAGCAGCTGGTGCCAAAACGGGACCATGCCCTCCTGGAGGAGCAGAGCAAGCAGCA GTCCAACGAGCACCTGCGCCGCCAGTTCGCCAGCCAGGCCAATGTTGTGGGGCCCTGGATCCAGACCAAGATGGAGGAGATCGGGCGCAT CTCCATTGAGATGAACGGGACCCTGGAGGACCAGCTGAGCCACCTGAAGCAGTATGAACGCAGCATCGTGGACTACAAGCCCAACCTGGA CCTGCTGGAGCAGCAGCACCAGCTCATCCAGGAGGCCCTCATCTTCGACAACAAGCACACCAACTATACCATGGAGCACATCCGCGTGGG CTGGGAGCAGCTGCTCACCACCATTGCCCGCACCATCAACGAGGTGGAGAACCAGATCCTCACCCGCGACGCCAAGGGCATCAGCCAGGA GCAGATGCAGGAGTTCCGGGCGTCCTTCAACCACTTCGACAAGGATCATGGCGGGGCGCTGGGGCCCGAGGAGTTCAAGGCCTGCCTCAT CAGCCTGGGCTACGACGTGGAGAACGACCGGCAGGGTGAGGCCGAGTTCAACCGCATCATGAGCCTGGTCGACCCCAACCATAGCGGCCT TGTGACCTTCCAAGCCTTCATCGACTTCATGTCGCGGGAGACCACCGACACGGACACGGCTGACCAGGTCATCGCTTCCTTCAAGGTCTT AGCAGGGGACAAGAACTTCATCACAGCTGAGGAGCTGCGGAGAGAGCTGCCCCCCGACCAGGCCGAGTACTGCATCGCCCGCATGGCGCC ATACCAGGGCCCTGACGCCGTGCCCGGTGCCCTCGACTACAAGTCCTTCTCCACGGCCTTGTATGGCGAGAGCGACCTGTGAGGCCCCAG AGACCTGACCCAACACCCCCGACGGCCTCCAGGAGGGGCCTGGGCAGCCCCACAGTCCCATTCCTCCACTCTGTATCTATGCAAAGCACT CTCTGCAGTCCTCCGGGGTGGGTGGGTGGGCAGGGAGGGGCTGGGGCAGGCTCTCTCCTCTCTCTCTTTGTGGGTTGGCCAGGAGGTTCC CCCGACCAGGTTGGGGAGACTTGGGGCCAGCGCTTCTGGTCTGGTAAATATGTATGATGTGTTGTGCTTTTTTAACCAAGGAGGGGCCAG TGGATTCCCACAGCACAACCGGTCCCTTCCATGCCCTGGGATGCCTCACCACACCCAGGTCTCTTCCTTTGCTCTGAGGTCCCTTCAAGG CCTCCCCAATCCAGGCCAAAGCCCCATGTGCCTTGTCCAGGAACTGCCTGGGCCATGCGAGGGGCCAGCAGAGGGCGCCACCACCACCTG ACGGCTGGGGACCCACCCAGCCCCTCTCCCCTCTCTGCTCCAGACTCACTTGCCATTGCCAGGAGATGGCCCCAACAAGCACCCCGCTTT TGCAGCAGAGGAGCTGAGTTGGCAGACCGGGCCCCCCTGAACCGCACCCCATCCCACCAGCCCCGGCCTTGCTTTGTCTGGCCTCACGTG TCTCAGATTTTCTAAGAACCAAAAAAAAAAAAGGAAAAAAAACACAAAACAACAAAAACCAAAAAAAAAAAAAATCACAAAAACAAAAAA ACTATAAAAAAGAAAGAATTAAAAACTTTCAGAGAATTACTATTTACTTTATTAACTTACGGATTTATTATATAAATATATATTCACCTA GCAACATATCTCTGCCGTCTCTCCTGCTCTCATAATGAAGACATAGCCGATTCTCTGCCCGGGCCCCTTGCTGATGCTCCTCCGGGTCTG CGTCGGGCGTGGGTCTCTGGGGACCCTCCAGAGGTGGAGGTGGGCTGATGGCCTGGCTGCCTGGTGGTTGATGGTTTTGCTCCCCCTACC TTTTTTTTTTGAGTTTATTCTGATTGATTTTTTTTCTTGGTTTCTGGATAAACCACCCTCTGGGGACAGGATAATAAAACATGTAATATT TTTAAGAAGGATTCCTGCAGCATCATCTTTTTTTATTTCTCCTGTGTCTGTCCTCCACCTTCTAGGAGAGCCAGGGCAGAGCTAGCACTG TCTTAAGCTGTCAACGTGGACTAGCTCGTGTCATCTGCTCGAGAAGGGCTGTCGCTGTTCTTGTTTCTGAGTGAGGAGTACGCAGGCCAG AGTGGTCACCCGGCCGTGAGCAGTGAGGGCCAGAGACTAGCCCCAGACAGGTGGATGCCAGAGAGAGTGGCACCCATGCCAGGCAAGGCC TAGGGAGGTGGTCTTGCTCAGCAACCCTGCCCTGAGCAGCAGGTGCGCCCATCCGGAGATCCTAGGAGAAGGTGGCCACCTCCATCCACT AAGGAAGAGAAGGAAGACAGTGGCTTGAGGCAGGGAGCTCGCAGGACAGAGCCTGAGCCACCCTGTCCCTCCCACCTGGCTCACCTGTCT GTGGGTCAGGCAGATGACCCCCTCACCCCCATCCAGGTGCTGGCTGCAGTGGCCTGTGCAGAGAGGGGCAGGGTGAGTGCCCACCAGTCC CCGTACCCCTTCCCCCCATGCCCCACCATGCCGGGGTGGTACTCACAGAAGATGCAGGTGAGGTGGGCCACACAGGACACGAACCGCTCG AAGTCCACACGCAGACGGCTATCCCGGTAGCGGCTGGTGAGGGTCTGGGTCAGCTGGTTGTTCAGGTGGAAGCCTAGGGGGAGGCTGCTT CTGAGCCCAGTGGCCCACAGGGAACCCACCTTGGCATTGCATCCCCACCCCACCTCCTCAGGGAGGACATGAATGCCACAGGGTGTCACA CCCCAACTCTGCCCCATCCCGGCAGGGTGAGTACAGGCTGATCCCTTCAATCCTCTGGGCCTGTTTCCTCATCCATCAAACGGACTAAGA CAGCCCCGACCCCATAGGGTGTGTGAAGACAGAACGCTCAGGACAGCGTCTGACACGTGACTCGATGTGTGGGTACTGTTACTCCTTAAA >102026_102026_1_ZNF416-ACTN4_ZNF416_chr19_58089425_ENST00000196489_ACTN4_chr19_39191240_ENST00000252699_length(amino acids)=908AA_BP=50 MALVAAVPGFPPRVARRSRPRSAHNPMAAAVLRDSTSVPVTAEAKLMGFTQTFTAWCNSHLRKAGTQIENIDEDFRDGLKLMLLLEVISG ERLPKPERGKMRVHKINNVNKALDFIASKGVKLVSIGAEEIVDGNAKMTLGMIWTIILRFAIQDISVEETSAKEGLLLWCQRKTAPYKNV NVQNFHISWKDGLAFNALIHRHRPELIEYDKLRKDDPVTNLNNAFEVAEKYLDIPKMLDAEDIVNTARPDEKAIMTYVSSFYHAFSGAQK AETAANRICKVLAVNQENEHLMEDYEKLASDLLEWIRRTIPWLEDRVPQKTIQEMQQKLEDFRDYRRVHKPPKVQEKCQLEINFNTLQTK LRLSNRPAFMPSEGKMVSDINNGWQHLEQAEKGYEEWLLNEIRRLERLDHLAEKFRQKASIHEAWTDGKEAMLKHRDYETATLSDIKALI RKHEAFESDLAAHQDRVEQIAAIAQELNELDYYDSHNVNTRCQKICDQWDALGSLTHSRREALEKTEKQLEAIDQLHLEYAKRAAPFNNW MESAMEDLQDMFIVHTIEEIEGLISAHDQFKSTLPDADREREAILAIHKEAQRIAESNHIKLSGSNPYTTVTPQIINSKWEKVQQLVPKR DHALLEEQSKQQSNEHLRRQFASQANVVGPWIQTKMEEIGRISIEMNGTLEDQLSHLKQYERSIVDYKPNLDLLEQQHQLIQEALIFDNK HTNYTMEHIRVGWEQLLTTIARTINEVENQILTRDAKGISQEQMQEFRASFNHFDKDHGGALGPEEFKACLISLGYDVENDRQGEAEFNR IMSLVDPNHSGLVTFQAFIDFMSRETTDTDTADQVIASFKVLAGDKNFITAEELRRELPPDQAEYCIARMAPYQGPDAVPGALDYKSFST -------------------------------------------------------------- >102026_102026_2_ZNF416-ACTN4_ZNF416_chr19_58089425_ENST00000196489_ACTN4_chr19_39191240_ENST00000424234_length(transcript)=1702nt_BP=298nt TTGCATACGGTAAGGCGGGACTTCCGGCACCGCTCCGAGATGGTAATTTTGGTGGTTCTCTACCTCGGCCCACGCCGCCTGAGTTAGAAA CGCTGCCTCCGGCACAGAGCGGGGGTCGCCCCGCTGCGCATCAGCCGGTGGGTCGCTGGCGCTGGTGGCAGCCGTGCCTGGGTTCCCGCC CCGGGTCGCCCGCCGCTCCCGGCCCCGCTCCGCTCACAATCCGATGGCGGCGGCCGTGCTTAGGGATTCGACTTCGGTTCCCGTGACTGC AGAAGCTAAACTTATGGGCTTTACACAGACCTTCACGGCATGGTGCAACTCCCACCTGCGGAAGGCAGGCACACAGATCGAGAACATTGA TGAGGACTTCCGAGACGGGCTCAAGCTCATGCTGCTCCTGGAGGTTCACGAGCTGGATTACTACGACTCCCACAATGTCAACACCCGGTG CCAGAAGATCTGTGACCAGTGGGACGCCCTCGGCTCTCTGACACATAGTCGCAGGGAAGCCCTGGAGAAAACAGAGAAGCAGCTGGAGGC CATCGACCAGCTGCACCTGGAATACGCCAAGCGCGCGGCCCCCTTCAACAACTGGATGGAGAGCGCCATGGAGGACCTCCAGGACATGTT CATCGTCCATACCATCGAGGAGATTGAGGGCCTGATCTCAGCCCATGACCAGTTCAAGTCCACCCTGCCGGACGCCGATAGGGAGCGCGA GGCCATCCTGGCCATCCACAAGGAGGCCCAGAGGATCGCTGAGAGCAACCACATCAAGCTGTCGGGCAGCAACCCCTACACCACCGTCAC CCCGCAAATCATCAACTCCAAGTGGGAGAAGGTGCAGCAGCTGGTGCCAAAACGGGACCATGCCCTCCTGGAGGAGCAGAGCAAGCAGCA GTCCAACGAGCACCTGCGCCGCCAGTTCGCCAGCCAGGCCAATGTTGTGGGGCCCTGGATCCAGACCAAGATGGAGGAGATCGGGCGCAT CTCCATTGAGATGAACGGGACCCTGGAGGACCAGCTGAGCCACCTGAAGCAGTATGAACGCAGCATCGTGGACTACAAGCCCAACCTGGA CCTGCTGGAGCAGCAGCACCAGCTCATCCAGGAGGCCCTCATCTTCGACAACAAGCACACCAACTATACCATGGAGCACATCCGCGTGGG CTGGGAGCAGCTGCTCACCACCATTGCCCGCACCATCAACGAGGTGGAGAACCAGATCCTCACCCGCGACGCCAAGGGCATCAGCCAGGA GCAGATGCAGGAGTTCCGGGCGTCCTTCAACCACTTCGACAAGGATCATGGCGGGGCGCTGGGGCCCGAGGAGTTCAAGGCCTGCCTCAT CAGCCTGGGCTACGACGTGGAGAACGACCGGCAGGGTGAGGCCGAGTTCAACCGCATCATGAGCCTGGTCGACCCCAACCATAGCGGCCT TGTGACCTTCCAAGCCTTCATCGACTTCATGTCGCGGGAGACCACCGACACGGACACGGCTGACCAGGTCATCGCTTCCTTCAAGGTCTT AGCAGGGGACAAGAACTTCATCACAGCTGAGGAGCTGCGGAGAGAGCTGCCCCCCGACCAGGCCGAGTACTGCATCGCCCGCATGGCGCC >102026_102026_2_ZNF416-ACTN4_ZNF416_chr19_58089425_ENST00000196489_ACTN4_chr19_39191240_ENST00000424234_length(amino acids)=519AA_BP=50 MALVAAVPGFPPRVARRSRPRSAHNPMAAAVLRDSTSVPVTAEAKLMGFTQTFTAWCNSHLRKAGTQIENIDEDFRDGLKLMLLLEVHEL DYYDSHNVNTRCQKICDQWDALGSLTHSRREALEKTEKQLEAIDQLHLEYAKRAAPFNNWMESAMEDLQDMFIVHTIEEIEGLISAHDQF KSTLPDADREREAILAIHKEAQRIAESNHIKLSGSNPYTTVTPQIINSKWEKVQQLVPKRDHALLEEQSKQQSNEHLRRQFASQANVVGP WIQTKMEEIGRISIEMNGTLEDQLSHLKQYERSIVDYKPNLDLLEQQHQLIQEALIFDNKHTNYTMEHIRVGWEQLLTTIARTINEVENQ ILTRDAKGISQEQMQEFRASFNHFDKDHGGALGPEEFKACLISLGYDVENDRQGEAEFNRIMSLVDPNHSGLVTFQAFIDFMSRETTDTD -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for ZNF416-ACTN4 |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 108_126 | 54.0 | 912.0 | VCL | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 108_126 | 0 | 693.0 | VCL | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 12_26 | 0 | 693.0 | VCL | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000390009 | 0 | 14 | 40_61 | 0 | 693.0 | VCL |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 12_26 | 54.0 | 912.0 | VCL | |
Tgene | ACTN4 | chr19:58089425 | chr19:39191240 | ENST00000252699 | 0 | 21 | 40_61 | 54.0 | 912.0 | VCL |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ZNF416-ACTN4 |
![]() (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for ZNF416-ACTN4 |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | C4551527 | Focal segmental glomerulosclerosis 1 | 9 | GENOMICS_ENGLAND;UNIPROT | |
Tgene | C0007097 | Carcinoma | 1 | CTD_human | |
Tgene | C0019193 | Hepatitis, Toxic | 1 | CTD_human | |
Tgene | C0024667 | Animal Mammary Neoplasms | 1 | CTD_human | |
Tgene | C0024668 | Mammary Neoplasms, Experimental | 1 | CTD_human | |
Tgene | C0205696 | Anaplastic carcinoma | 1 | CTD_human | |
Tgene | C0205697 | Carcinoma, Spindle-Cell | 1 | CTD_human | |
Tgene | C0205698 | Undifferentiated carcinoma | 1 | CTD_human | |
Tgene | C0205699 | Carcinomatosis | 1 | CTD_human | |
Tgene | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human | |
Tgene | C1257925 | Mammary Carcinoma, Animal | 1 | CTD_human | |
Tgene | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human | |
Tgene | C1868672 | NEPHROTIC SYNDROME, STEROID-RESISTANT, AUTOSOMAL RECESSIVE | 1 | ORPHANET | |
Tgene | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human | |
Tgene | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human | |
Tgene | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |